

# Meet the Team Driving Personalized Cell & Gene Therapy Clinical Development

When revolutionizing meaningful care for patients, you need a partner as innovative and dedicated to your program as you are. Worldwide Clinical Trials' Cell and Gene Therapy Hub collaborates with drug development partners like you, working to advance novel and complex cell and gene therapy programs through clinical development. From critical non-clinical and chemistry, manufacture, and control information to real-world evidence generation of long-term follow-up studies and everything in between, we are here to drive your program's success.

Our teams were constructed with flexibility and adaptability in mind, bringing together the scientific, medical, operational, and regulatory expertise into one integrated and versatile unit. Our experts adopt a collaborative approach that leverages the lessons learned day in and day out of developing these programs and customize their approach to the unique needs of your study. We know no two studies are alike—and we work with each of our sponsors to deliver the personalized experience their program needs.

## The strategic and scientific leads in our Hub have:



**10+ average years** of cell and gene therapy experience



**Supported 165+** cell and gene therapy trials



An **average of 50+** cell and gene therapy publications and presentations

## Meet Your Cell & Gene Therapy Hub Team

Our cell and gene therapy team has delivered cell therapy and gene therapy studies across North America and Europe in all therapeutic areas and modalities. Leveraging our diverse and extensive experience, we develop a custom, integrated approach for each and every sponsor we support.



**Amy Raymond, PhD, PMP**  
Executive Director, Therapeutic Strategy  
Lead, Cellular and Genetic Medicines

- 25+ years of drug discovery and development experience and has provided provided strategic support to more than 50 cell and gene therapy studies across Phase I-IV and all therapeutic areas
- Leads strategic guidance for cell and gene therapy development programs at all stages, especially for programs serving rare and complex diseases



**Virgilio Garcia Lerma**  
Executive Director, Global  
Regulatory Strategy

- 20+ years of global clinical research experience
- Heads the strategic regulatory pre-award team and provides strategic advice on regulatory clinical development for Phase I-IV trials



**Derek Ansel, MS, LCGC**  
Vice President, Therapeutic Strategy Lead,  
Rare Disease

- 12+ years in global rare and pediatric clinical research
- Leads rare disease and pediatric corporate strategy and drives patient-focused advocacy initiatives; board-certified genetic counselor



**Michael F. Murphy, MD, PhD**  
Chief Medical and Scientific Officer

- 30+ years of clinical research experience
- Co-founder of Worldwide and provides early engagement technical and scientific support relevant to clinical trial methodology and regulatory engagement for collaborative drug development

# Meet Your Cell & Gene Therapy Hub Team



**Jose Rodriguez Ciancio, MD**  
Medical Director, Medical Affairs, Immune-Mediated & Inflammatory Diseases

- Trained in pediatrics, with MSc in personalized medicine and novel therapies
- Experience in Phase I-IV global clinical research, leveraging experience in biotech clinical development, as sub-investigator at investigational site and medical monitor in a global CRO



**Juliane K. Mills, MS, MPH**  
Senior Director, Therapeutic Strategy Lead, Rare Disease

- 23+ years of global clinical research experience
- Provides operational strategies that are efficient and effective for delivering rare disease trials while being accessible to patients, caregivers, and families



**Dana F. Durst**  
Executive Director, Site Activation & Regulatory Therapeutic Lead, Oncology

- 16+ years of clinical research experience, including 6+ years in cell and gene therapy development
- Heads the Global Site Activation Management Team within Worldwide's Oncology Business Unit, overseeing all aspects of startup activities globally across Phase I-IV programs




**Nathan Chadwick**  
Senior Director, Therapeutic Strategy Lead, Rare Disease

- 10+ years of Phase I-IV global clinical research experience
- Champions fit-for-purpose and efficient strategies that incorporate the patient voice



**Jake Boyd**  
Senior Director, Project Management, Oncology

- 10+ years of Phase I-III clinical research experience, with a primary focus on first-in-human dose-escalation/expansion studies
- 5+ years focused on the development and oversight of cell and gene therapies in both solid tumor and hematology




**Megan Roberts**  
Director, Project Management, Immune-Mediated & Inflammatory Diseases

- Phase I-III clinical research experience at investigational site and global CROs
- Specialized in cell therapy development, experience across diverse modalities for rare and complex diseases



**Kunle Oshin, MD**  
Director, Project Management, Cardiometabolic & Inflammatory Diseases

- Trained physician anaesthesiologist with 22+ years of experience in global Phase I-IV clinical research, including 11+ years in project management in multiple therapeutic areas
- 12+ years of experience in rare disease cell and gene therapy development



**Simran Padam, MD**  
Medical Director, Medical Affairs, Oncology

- 10+ years of experience in global Phase I first-in-human to Phase III clinical research as a research coordinator, researcher, and medical monitor for academia, CROs, and investigative sites
- Extensive experience in adoptive cell therapy development programs



**Anthony Poynton**  
Executive Director, Project Management, Immune-Mediated & Inflammatory Diseases

- Nearly 25 years of global CRO and pharma experience in global Phase I-IV clinical trials
- Experience working on large, complex studies across several therapeutic areas